Q32 Bio (QTTB) stock
Follow QTTB's trial news. Members get an alert when Q32 Bio files news, and see its trials, share raises, and its CEO's filings.
What's next for QTTB, and how long its cash lasts
From Q32 Bio’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
Over 5 years
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why it's down
Down 25% in 3 months, 31% under its 50-day average.
Down more than its industry: the 275 other stocks in it fell a median 12% over the same 3 months.
−1Size $261M, micro cap
1 more thing pulling QTTB's score down, for members
What's next
Expected to report Thu Nov 12, before the open
After its last 4 reports it closed +3.1% on average, higher 3 of 4 times.
What would move QTTB's score: 4 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
QTTB has 3 of 14 checks firing
One per group is shown here.
How QTTB ranks in Biotech
QTTB is #72 of 276 by Quality Score. The top three are shown with their scores, and the rest by name.
ABCL10/1420
EXEL9/1419
RGEN7/1419
ONCOpen for its score
PBYIOpen for its score
QTTB3/146
When does QTTB report, and what happens after?
Expected to report Thu Nov 12, before the open (in 43 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 5, 2026Before open | Before open | -0.0% | +2.1% | -4.6% |
| May 5, 2026Before open | Before open | 0.0% | +2.0% | +2.8% |
| Mar 10, 2026Before open | Before open | 0.0% | +17.4% | +23.5% |
| Nov 13, 2025Before open | Before open | -2.9% | -9.1% | -12.8% |
Who is trading QTTB
Insiders
2 insiders bought $30M across 4 filings, and 3 insiders sold $275K across 3 filings, in the last 6 months. The newest:
About Q32 Bio
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of QTTB's score, with the points and the reason
- All 14 checks on QTTB and on all 2,952 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on QTTB
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.